TY - JOUR
T1 - Influence of PDLA nanoparticles size on drug release and interaction with cells
AU - Cartaxo, Ana Luísa
AU - Costa-Pinto, Ana R.
AU - Martins, Albino
AU - Faria, Susana
AU - Gonçalves, Virgínia M. F.
AU - Tiritan, Maria Elizabeth
AU - Ferreira, Helena
AU - Neves, Nuno M.
N1 - Funding Information:
The authors would like to acknowledge the Portuguese Foundation for Science and Technology for the Post-doc fellowships (SFRH/BPD/90332/2012 and SFRH/BPD/38939/2007), as well as to the QREN (project “RL2 -SCN - NORTE-07-0124-FEDER-000018” co-financed by the North Portugal Regional Operational Program [ON.2, O Novo Norte] under the NSRF through the ERDF) for financing this research work.
Funding Information:
Additional Supporting Information may be found in the online version of this article. Correspondence to: N. M. Neves; e-mail: [email protected]. Contract grant sponsor: QREN project “RL2-SCN-NORTE-07-0124-FEDER-000018” co-financed by the North Portugal Regional Operational Program (ON.2, O Novo Norte) under the NSRF through the ERDF Contract grant sponsor: Portuguese Foundation for Science and Technology; contract grant number: SFRH/BPD/38939/2007 and SFRH/ BPD/90332/2012
Publisher Copyright:
© 2018 Wiley Periodicals, Inc.
PY - 2019/3
Y1 - 2019/3
N2 - Polymeric nanoparticles (NPs) are strong candidates for the development of systemic and targeted drug delivery applications. Their size is a determinant property since it defines the NP–cell interactions, drug loading capacity, and release kinetics. Herein, poly(d,l-lactic acid) (PDLA) NPs were produced by the nanoprecipitation method, in which the influence of type and concentration of surfactant as well as PDLA concentration were assessed. The adjustment of these parameters allowed the successful production of NPs with defined medium sizes, ranging from 80 to 460 nm. The surface charge of the different NPs populations was consistently negative. Prednisolone was effectively entrapped and released from NPs with statistically different medium sizes (i.e., 80 or 120 nm). Release profiles indicate that these systems were able to deliver appropriate amounts of drug with potential applicability in the treatment of inflammatory conditions. Both NPs populations were cytocompatible with human endothelial and fibroblastic cells, in the range of concentrations tested (0.187–0.784 mg/mL). However, confocal microscopy revealed that within the range of sizes tested in our experiments, NPs presenting a medium size of 120 nm were able to be internalized in endothelial cells. In summary, this study demonstrates the optimization of the processing conditions to obtain PDLA NPs with narrow size ranges, and with promising performance for the treatment of inflammatory diseases.
AB - Polymeric nanoparticles (NPs) are strong candidates for the development of systemic and targeted drug delivery applications. Their size is a determinant property since it defines the NP–cell interactions, drug loading capacity, and release kinetics. Herein, poly(d,l-lactic acid) (PDLA) NPs were produced by the nanoprecipitation method, in which the influence of type and concentration of surfactant as well as PDLA concentration were assessed. The adjustment of these parameters allowed the successful production of NPs with defined medium sizes, ranging from 80 to 460 nm. The surface charge of the different NPs populations was consistently negative. Prednisolone was effectively entrapped and released from NPs with statistically different medium sizes (i.e., 80 or 120 nm). Release profiles indicate that these systems were able to deliver appropriate amounts of drug with potential applicability in the treatment of inflammatory conditions. Both NPs populations were cytocompatible with human endothelial and fibroblastic cells, in the range of concentrations tested (0.187–0.784 mg/mL). However, confocal microscopy revealed that within the range of sizes tested in our experiments, NPs presenting a medium size of 120 nm were able to be internalized in endothelial cells. In summary, this study demonstrates the optimization of the processing conditions to obtain PDLA NPs with narrow size ranges, and with promising performance for the treatment of inflammatory diseases.
KW - Cell internalization
KW - Cytocompatibility
KW - PDLA nanoparticles
KW - Prednisolone
KW - Size distribution
UR - http://www.scopus.com/inward/record.url?scp=85057459610&partnerID=8YFLogxK
U2 - 10.1002/jbm.a.36563
DO - 10.1002/jbm.a.36563
M3 - Article
C2 - 30485652
AN - SCOPUS:85057459610
SN - 1549-3296
VL - 107
SP - 482
EP - 493
JO - Journal of Biomedical Materials Research - Part A
JF - Journal of Biomedical Materials Research - Part A
IS - 3
ER -